The Relationship Between Thyroid Function and Body Composition, Leptin, Adiponectin, and Insulin Sensitivity in Morbidly Obese Euthyroid Subjects Compared to Non-obese Subjects.
Thyroid function
adiponectin
insulin resistance
leptin
obesity
Journal
Clinical medicine insights. Endocrinology and diabetes
ISSN: 1179-5514
Titre abrégé: Clin Med Insights Endocrinol Diabetes
Pays: United States
ID NLM: 101578235
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
10
2020
accepted:
18
12
2020
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
Thyroid function tests (TFTs) changes in obese people have been studied with increasing interest, however, studies have been inconsistent hence it remains poorly understood. We compared the TFTs of morbidly obese euthyroid Saudi subjects with non-obese controls and then we examined the influence of leptin, adiponectin, and insulin resistance on TFTs. Fifty-five euthyroid obese subjects attending bariatric surgery clinic and 52 non-obese age-and gender-matched controls were recruited. We measured body weight, BMI, body composition, thyroid-stimulating hormone (TSH), Free T4 (FT4), Free T3(FT3), thyroid antibodies, fasting leptin, adiponectin, and lipid profile. Insulin resistance was quantified by HOMA-IR. Data are presented as mean ± SEM. Mean BMI was 45.6 ± 1.5 and 23.2 ± 0.5 kg/m We report a small increase in TSH and a small decrease in FT3 within the normal range in obese subjects compared to non-obese controls. We also report a positive correlation between TSH and BMI with increased odds ratio of becoming obese with the increase in TSH and decrease in FT3. These changes may be either causally related or adaptive to the obesity state. FT4 and FT3 seem to correlate with leptin (but not with adiponectin or HOMA-IR) in the non-obese controls only. Larger mechanistic studies are needed to further elucidate the interesting association between obesity and TFTs.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
Thyroid function tests (TFTs) changes in obese people have been studied with increasing interest, however, studies have been inconsistent hence it remains poorly understood. We compared the TFTs of morbidly obese euthyroid Saudi subjects with non-obese controls and then we examined the influence of leptin, adiponectin, and insulin resistance on TFTs.
SUBJECTS/METHODS
METHODS
Fifty-five euthyroid obese subjects attending bariatric surgery clinic and 52 non-obese age-and gender-matched controls were recruited. We measured body weight, BMI, body composition, thyroid-stimulating hormone (TSH), Free T4 (FT4), Free T3(FT3), thyroid antibodies, fasting leptin, adiponectin, and lipid profile. Insulin resistance was quantified by HOMA-IR. Data are presented as mean ± SEM.
RESULTS
RESULTS
Mean BMI was 45.6 ± 1.5 and 23.2 ± 0.5 kg/m
CONCLUSIONS
CONCLUSIONS
We report a small increase in TSH and a small decrease in FT3 within the normal range in obese subjects compared to non-obese controls. We also report a positive correlation between TSH and BMI with increased odds ratio of becoming obese with the increase in TSH and decrease in FT3. These changes may be either causally related or adaptive to the obesity state. FT4 and FT3 seem to correlate with leptin (but not with adiponectin or HOMA-IR) in the non-obese controls only. Larger mechanistic studies are needed to further elucidate the interesting association between obesity and TFTs.
Identifiants
pubmed: 33613038
doi: 10.1177/1179551420988523
pii: 10.1177_1179551420988523
pmc: PMC7868467
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1179551420988523Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83
pubmed: 10092513
Mol Cell Endocrinol. 2010 Mar 25;316(2):165-71
pubmed: 19540303
Clin Endocrinol (Oxf). 2006 Feb;64(2):125-8
pubmed: 16430708
J Clin Endocrinol Metab. 2005 Jul;90(7):4019-24
pubmed: 15870128
J Thyroid Res. 2017;2017:5739806
pubmed: 28630779
Eur J Endocrinol. 2009 Mar;160(3):403-8
pubmed: 19073832
Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1595-9
pubmed: 10845877
J Clin Endocrinol Metab. 2010 Aug;95(8):3614-7
pubmed: 20685890
Eur J Endocrinol. 1997 Dec;137(6):659-63
pubmed: 9437233
Rev Endocr Metab Disord. 2014 Jun;15(2):149-56
pubmed: 24170312
Thyroid. 1997 Jun;7(3):407-9
pubmed: 9226211
Clin Endocrinol (Oxf). 2007 Aug;67(2):265-9
pubmed: 17547687
Regul Pept. 2000 Aug 25;92(1-3):25-9
pubmed: 11024561
J Cell Biochem. 2004 Oct 15;93(3):491-6
pubmed: 15372626
Endocrinology. 2004 May;145(5):2221-7
pubmed: 14764630
Clin Chim Acta. 2012 Feb 18;413(3-4):396-405
pubmed: 22130312
Clin Endocrinol (Oxf). 2005 Apr;62(4):487-91
pubmed: 15807881
Eur J Endocrinol. 2002 Aug;147(2):173-80
pubmed: 12153737
Arch Intern Med. 2008 Mar 24;168(6):587-92
pubmed: 18362250
Clin Endocrinol (Oxf). 2003 Nov;59(5):621-9
pubmed: 14616887
J Endocrinol. 2003 Jan;176(1):7-12
pubmed: 12525244
Endocrine. 2004 Jul;24(2):147-53
pubmed: 15347841
J Biol Chem. 1995 Nov 10;270(45):26746-9
pubmed: 7592907
Nature. 1994 Dec 1;372(6505):425-32
pubmed: 7984236
J Clin Endocrinol Metab. 1997 Apr;82(4):1118-25
pubmed: 9100583
Eur J Endocrinol. 2013 Aug 28;169(3):339-47
pubmed: 23811187
Am J Med Sci. 1991 May;301(5):310-3
pubmed: 2021153
Lipids. 1993 Feb;28(2):151-5
pubmed: 8441340
Obes Rev. 2007 Jan;8(1):21-34
pubmed: 17212793
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
J Clin Endocrinol Metab. 2005 Aug;90(8):4659-63
pubmed: 15914521
J Clin Endocrinol Metab. 2010 Aug;95(8):3965-72
pubmed: 20534769
Horm Res Paediatr. 2017;88(2):140-146
pubmed: 28614818
J Intern Med. 2000 Oct;248(4):299-308
pubmed: 11086640
Int J Obes (Lond). 2009 Jan;33(1):166-72
pubmed: 19050673